|
| Seroconcordance n (%) | Serodiscordance n (%) | OR (IC95%) | p |
| Clinical condition |
| 0.549 | ||
| Good | 109 (26.14) | 281 (67.39) | 1 |
|
| Poor | 9 (2.16) | 18 (4.31) | 0.78 (0.34 - 1.78) |
|
| Clinical stage (WHO) |
| 0.714 | ||
| Stage 1 | 92 (22.06) | 239 (57.31) | 1 |
|
| Stage 2 | 14 (3.36) | 37 (8.87) | 1.02 (0.54 - 1.97) | 0.959 |
| Stage 3 and 4 | 12 (2.88) | 23 (5.52) | 0.74 (0.35 - 1.54) | 0.419 |
| Circumstance of discovery of infection |
| 0.158 | ||
| PMTCTa | 56 (13.43) | 152 (36.45) | 1 |
|
| Hospital contact | 38 (9.11) | 78 (18.70) | 0.75 (0.45 - 1.22) | 0.247 |
| Voluntary testing | 20 (4.80) | 66 (15.83) | 01.23 (0.69 - 2.22) | 0.481 |
| Family screening | 4 (0.96) | 3 (0.72) | 0.28 (0.06 - 1.27) | 0.099 |
| Viral load at last check-up |
| 0.069 | ||
| Detectable | 28 (6.72) | 48 (11.51) | 1 |
|
| undetectable | 90 (21.58) | 251 (60.19) | 1.63 (0.96 - 2.75) |
|
| ART compliance |
|
| 0.337 | |
| Good | 97 (23.26) | 257 (61.63) | 1 |
|
| Poor | 21 (5.04) | 42 (10.07) | 1.32 (0.75 - 2.35) |
|